| Project name: | REcombinant TEchnologies for MEDicine |
| ID: | TN02000122 |
| Acronym: | RETEMED |
| Supported by: | Technology Agency of the Czech Republic |
| Programme: | National Centres of Competence 1: Support programme for applied research, experimental development and innovation (NCK 2 – STA02022TN020) |
| Project duration: | 01/2023 – 12/2028 (72 months) |
| Budget: | Total budget/eligible costs: 526 679 413 CZK of which Public support 416 635 779 CZK of which support for CIIRC CTU: 20 140 038 CZK |
| Principal investigator at CIIRC: | Dr. Josef Šivic |
| Project Coordinator / Main Beneficiary: | Palacký University Olomouc (UPOL) – Faculty of Medicine and Dentistry |
| Other Project Partners: | 2. Biotechnologický ústav AV ČR, v. v. i. 3. Univerzita Jana Evangelisty Purkyně v Ústí nad Labem 4. Univerzita Karlova 5. Vysoká škola chemicko-technologická v Praze 6. Fakultní nemocnice u sv. Anny v Brně 7. Ústav makromolekulární chemie AV ČR, v. v. i. 8. Ústav molekulární genetiky AV ČR, v. v. i. 9. České vysoké učení technické v Praze 10. DYNTEC spol. s r.o. 11. APIGENEX s.r.o. 12. Enantis s.r.o. 13. BLOCK a.s. 14. KORTAN spol. s r.o. 15. AUMED, a.s. 16. BLOCK SVP s.r.o. |
| Results: | Latest results |
| Subproject: | ID: TN02000122/001N – Therapeutics of Recombinant and Natural Origin (TEREP) Duration: 01/2023 – 06/2026 Aim of the sub-project: The TEREP project is an extension of the RETEMED project, enabling efficient use of the infrastructure and human resources of all teams in the RETEMED consortium. The sub-project addresses the following research sub-themes: 1. System for predictive diagnostics 2. Safe radioprotectant 3. Preventive programme to increase resistance to ionizing radiation – radioprotectants of synthetic and natural origin 4. Genetically modified specialized prokaryotic and eukaryotic cell lines for the production of recombinant antigens in bioreactors 5. Snake venom products for dermatology, pharmacy and the preparation of snakebite antisera Recombinant vaccine against cryptosporidiosis 6. Engineering biotherapeutics: engineering recombinant proteins for diagnostics and therapy Planned Outcomes: Ztech – proven technology – 6x; Zpolop – semi-completion – 1x; R – software – 2x; Gfunk – functional sample – 6x; S – specialized expert database – 1x |
Annotation:
Establishment of a centre of competence to achieve application potential in the field of recombinant drug preparation through the integration of research centres built within OP RDI/RDE. Building of research platform for the development of the Czech biotechnology and pharmaceutical industry and the renewal of the Institute of Sera and Vaccines. Development of recombinant proteins, molecular adjuvants, and carrier systems for the production of vaccines and therapeutics in treatment and prevention of infectious diseases, allergies, cerebrovascular and inflammatory diseases, and development of advanced analytical and diagnostic methods using nanomaterials. Development of a comprehensive mobile container system for vaccine production in emergencies (disasters, war operations, etc.).
